FDA to Create New Regulatory Framework for CBD

By Dean Seal

The Food and Drug Administration plans to create a new regulatory framework for products containing cannabidiol, the nonintoxicating variety of cannabis plant widely known as CBD.

The regulator said Thursday that after convening a working group to evaluate CBD products, it has concluded that the existing regulatory pathways for food and supplements isn't appropriate for CBD, which has surged in popularity and become widely available in recent years.

According to the FDA, CBD use raises a variety of safety concerns, including potential liver damage, adverse interactions with certain medications and potential harm to the male reproductive system.

The FDA said its current authorities over foods and dietary supplements offer it only limited tools for managing those risks.

The agency plans to work with Congress to establish stronger oversight of CBD products.

Write to Dean Seal at [e-mail]

(END) Dow Jones Newswires

01-26-23 1146ET